Broughton A, Strong J E, Crooke S T, Prestayko A W, Knight J
Cancer Treat Rep. 1979 Nov-Dec;63(11-12):1829-32.
Antibodies were raised against a new antineoplastic agent, tallysomycin, for use in a radioimmunoassay. The assay was sensitive to 2.5 ng of tallysomycin, had a coefficient of variation of 10.5% at 50 ng/ml, and was highly specific for tallysomycin A. The antibody exhibited reduced cross-reactivity with closely related tallysomycin analogs and little or no immunoreactivity with other antitumor antibiotics including bleomycin and phleomycin. Increased immunoreactivity occurred following copper chelation of tallysomycin B as compared with the non-chelated forms, thus indicating possible conformational alterations upon metal binding.
制备了针对新型抗肿瘤药物 tallysomycin 的抗体，用于放射免疫分析。该分析对 2.5 ng 的 tallysomycin 敏感，在 50 ng/ml时有 10.5% 的变异系数，且对 tallysomycin A 具有高度特异性。该抗体与密切相关的 tallysomycin 类似物的交叉反应性降低，与包括博来霉素和腐草霉素在内的其他抗肿瘤抗生素几乎没有免疫反应性。与未螯合形式相比，tallysomycin B 经铜螯合后免疫反应性增加，因此表明金属结合后可能发生构象改变。
